News archive

Filter by: Reset

December 2018

- 17 December 2018
- KBI Biopharma
Teneobio and Selexis Enter Second Services Agreement to Develop Research Cell Banks as Teneobio Prepares to Advance T...

Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignan...
- 13 December 2018
- Crown Bioscience
Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services

~ Services and Capacity Increase with New Site Opening ~
- 3 December 2018
- KBI Biopharma
KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board

Industry Experts to Provide Strategic Guidance as the Companies Advance Technologies Used in the Discovery, Analytics and Manufacturing of Difficult-to-Express Biologics

- 15 November 2018
- Crown Bioscience
New Pancreatic Ductal Adenocarcinoma Research Published in Journal of Visualized Experiments

Paper describes well-established protocols for PDAC orthotopic tumor homograft model development and immunoprofiling
- 8 November 2018
- Crown Bioscience
Crown Bioscience Expands Cardiovascular & Metabolic Disease Research Capability

The Company Offers New Non-GLP Services & Translational Rodent Models at its expanded site in Louisiana

- 25 October 2018
- Crown Bioscience
CrownBio Releases MuBase® 2.0. An Open Access Database of Immuno-Oncology Murine Models

Updates enhance user experience, provide comprehensive characterization data, and add new models
- 18 October 2018
- KBI Biopharma
Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform

Effort Designed to Safely and Efficiently Speed Drug Candidates into the Clinic
- 2 October 2018
- KBI Biopharma
CytoSen Therapeutics and KBI Biopharma Enter into Strategic Partnership to Manufacture NK Cells and Nanoparticles

Implementing scalable manufacturing processes to enable cGMP production of investigational Natural Killer cell therapies

- 26 September 2018
- KBI Biopharma
Selexis and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain Treatment into the Clinic

Selexis SUREtechnology Platform™ Successfully Expresses Hoba’s HB-086 in CHO Cells
- 26 September 2018
- Crown Bioscience
CrownBio Completes Validation of Prostate Cancer Patient-Derived Xenograft (PDX) Models

Unique well-characterized prostate models derived from castration resistant and hormone sensitive primary tissue now available for studies
- 18 September 2018
- Crown Bioscience
CrownBio Licenses Translational Breast Cancer Models of Resistance and Metastasis

CrownBio will market a set of new, highly characterized breast cancer models alongside their industry leading collection of more than 2500 PDX models (HuPrime®).
- 18 September 2018
- JSR Corporation
Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.

1 of 4